866-997-4948(US-Canada Toll Free)

Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

Published By :

GBI Research

Published Date : Jan 2015

Category :

Ovarian Cancer

No. of Pages : N/A

 

GBI Research, a leading business intelligence provider, has released its latest research report: “Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches”. The report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).

 

Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients.

 

Although the current developmental pipeline is quite crowded, efficacy with these late-stage drugs has been poor, at best demonstrating minimal improvements in progression-free survival, but not overall survival. The promising investigational drug candidates olaparib and trebananib are expected to gain approval during the forecast period. However, even on approval they are not expected to have a high market penetration, owing to their minimal therapeutic efficacy and anticipated premium prices. As a result, the OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.

 

Despite the poor clinical performance of current late-stage pipeline drugs, there is evidence of continued interest in the OC market, with a high number of drug candidates in the initial developmental pipeline, particularly at the Preclinical phase. There is a wide range of novel molecular targets distributed among these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in others in oncology.

 

Scope

 

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes:

 

  • A brief introduction to OC, including the disease’s pathogenesis, risk factors and diagnosis
  • In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
  • A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
  • Discussion of the drivers and barriers for market growth
  • In-depth analysis of licensing and co-development deals involving drugs indicated in OC, including an outline of the key deals

 

Reasons To Buy

 

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to:

 

  • Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm
  • Understand the key signaling pathways and molecular targets currently under investigation in OC drug development
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
  • Observe the trends in clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for OC therapeutics
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the OC therapeutics market

 

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

 

2 Introduction

2.1 Disease Pathophysiology

2.1.1 Ovarian Cancer – A Group of Distinct Diseases

2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways

2.2 Symptoms and Diagnosis

2.3 Risk Factors

2.3.1 Age

2.3.2 Inherited Genetic Mutations

2.3.3 Greater Number of Lifetime Ovulations

2.3.4 Weight

2.3.5 Previous Medical Conditions

2.4 Treatment Algorithm

2.4.1 Surgery

2.4.2 First-Line Chemotherapy

2.4.3 Maintenance Therapy

2.5 Recurrent Disease

 

3 Marketed Products

3.1 Carboplatin

3.2 Paclitaxel

3.3 Gemcitabine

3.4 Topotecan

3.5 Pegylated Liposomal Doxorubicin

3.6 Yondelis

3.7 Avastin

 

4 Product Pipeline

4.1 Overview of Pipeline by Phase and Route of Administration

4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target

4.2.1 Molecular Targets in the Developmental Pipeline

4.3 Clinical Trials

4.3.1 Clinical Trial Duration

4.3.2 Clinical Trial Size

4.3.3 Failure Rate

4.3.4 Discussion

4.4 Late-Stage Drugs in Developmental Pipeline

4.4.1 Niraparib

4.4.2 Olaparib

4.4.3 Vargatef

4.4.4 Trebananib

4.4.5 Farletuzumab

4.4.6 Karenitecin

4.5 Discussion

 

5 Market Forecasts

5.1 Asia-Pacific

5.1.1 Overview

5.1.2 Treatment Use Patterns and Revenues in Asia-Pacific Markets

5.2 India

5.2.1 Treatment Use Patterns

5.2.2 Annual Cost of Therapy

5.2.3 Market Forecast

5.3 China

5.3.1 Treatment Use Patterns

5.3.2 Annual Cost of Therapy

5.3.3 Market Forecast

5.4 Japan

5.4.1 Treatment Use Patterns

5.4.2 Annual Cost of Therapy

5.4.3 Market Forecast

5.5 Australia

5.5.1 Treatment Use Patterns

5.5.2 Annual Cost of Therapy

5.5.3 Market Forecast

5.6 Drivers and Barriers

5.6.1 Drivers

5.6.2 Barriers

 

6 Deals

6.1 Licensing Deals

6.1.1 Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338

6.1.2 PharmaMar Enters into Licensing Agreement with Janssen for Yondelis

6.1.3 Hana Enters into Licensing Agreement with Tekmira

6.1.4 AstraZeneca Enters into Licensing Agreement with Merck for MK-1775

6.1.5 Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug

6.1.6 Oasmia Enters into Licensing Agreement with Medison for Paclical

6.1.7 Orion Enters into Agreement with Oasmia

6.1.8 Ohio University Enters into Licensing Agreement with Phosplatin

6.1.9 Genta Enters into Licensing Agreement with Daiichi Sankyo

6.1.10 Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research

6.1.11 NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300

6.2 Co-development Deals

6.2.1 Bristol-Myers Squibb Enters into Co-development Agreement with Ono Pharma

6.2.2 Merck Enters into Co-development Agreement with Endocyte for Cancer Drug

6.2.3 Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre

6.2.4 Almac Discovery Enters into an Agreement with Queen’s University Belfast for Drug Discovery

 

7 Appendix

7.1 All Pipeline Drugs by Phase

7.1.1 Discovery

7.1.2 Preclinical

7.1.3 IND/CTA-Filed

7.1.4 Phase I

7.1.5 Phase II

7.1.6 Phase III

7.1.7 Pre-Registration

7.2 Market Forecasts to 2020

7.2.1 Asia-Pacific

7.2.2 India

7.2.3 China

7.2.4 Japan

7.2.5 Australia

7.3 Abbreviations

7.4 Bibliography

7.5 Research Methodology

7.5.1 Coverage

7.5.2 Secondary Research

7.5.3 Primary Research

7.5.4 Therapeutic Landscape

7.5.5 Geographical Landscape

7.5.6 Pipeline Analysis

7.6 Expert Panel Validation

7.7 Contact Us

7.8 Disclaimer

List of Table

 

Table 1: Ovarian Cancer Therapeutics, Histological Subtypes and Associated Genetic Mutations

Table 2: Ovarian Cancer Therapeutics, Affected Signaling Pathways in Ovarian Cancer, Associated Mutations and Effects on Cancer Development

Table 3: Ovarian Cancer Therapeutics, Ovarian Cancer Disease Staging

Table 4: Ovarian Cancer Therapeutics, Eastern Cooperative Oncology Group Performance Status Scores and Description

Table 5: Ovarian Cancer Therapeutics, Common Endpoints in Ovarian Cancer and Details of Criteria

Table 6: Ovarian Cancer Therapeutics, Rates of Sensory and Motor Neuropathy with Pegylated Liposomal Doxorubicin and Paclitaxel in Combination with Carboplatin (%), 2010

Table 7: Ovarian Cancer Therapeutics, Yondelis Phase III Clinical Trial, Patient Stratification by Platinum-Free Interval, 2010

Table 8: Ovarian Cancer Therapeutics, Poly ADP Ribose Polymerase Inhibitors Under Development, 2014

Table 9: Ovarian Cancer Therapeutics, Epidermal Growth Factor Receptor Inhibitors Under Development, 2014

Table 10: Ovarian Cancer Therapeutics, Mucin Inhibitors Under Development, 2014

Table 11: Ovarian Cancer Therapeutics, Aurora Kinase Inhibitors Under Development, 2014

Table 12: Ovarian Cancer Therapeutics, Average Clinical Trial Duration across Each Phase for Ovarian Cancer, across Oncology and Entire Industry (months), 2014

Table 13: Ovarian Cancer Therapeutics, Global, Patient Demographics of a Phase III Clinical Trial of Trebananib (%), 2011

Table 14: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Discovery Phase, 2014

Table 15: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Preclinical Phase, 2014T

Table 16: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, IND/CTA-Filed, 2014

Table 17: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Phase I, 2014

Table 18: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Phase II, 2014

Table 19: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Phase III, 2014

Table 20: Ovarian Cancer Therapeutics, Global, Developmental Pipeline, Pre-Registration, 2014

Table 21: Ovarian Cancer Therapeutics, Asia-Pacific, Market Forecast, 2013–2020

Table 22: Ovarian Cancer Therapeutics, India, Market Forecast, 2013–2020

Table 23: Ovarian Cancer Therapeutics, China, Market Forecast, 2013–2020

Table 24: Ovarian Cancer Therapeutics, Japan, Market Forecast, 2013–2020

Table 25: Ovarian Cancer Therapeutics, Australia, Market Forecast, 2013–2020

Table 26: Abbreviations

List of Chart

Figure 1: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, First-Line and Maintenance Therapies

Figure 2: Ovarian Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, First-Line and Maintenance Therapies

Figure 3: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, Recurrent Disease: All Patients

Figure 4: Ovarian Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, Recurrent Disease: All Patients

Figure 5: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, Recurrent Disease: Platinum-Sensitive

Figure 6: Ovarian Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, Recurrent Disease: Platinum-Sensitive

Figure 7: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters – Marketed Products, Recurrent Disease: Platinum-Resistant

Figure 8: Ovarian Cancer Therapeutics, Safety Results for Key Parameters – Marketed Products, Recurrent Disease: Platinum-Resistant

Figure 9: Ovarian Cancer Therapeutics, Global, Pipeline Distribution by Stage, Program Type and Route of Administration, 2014

Figure 10: Ovarian Cancer Therapeutics: Global, Pipeline by Molecule Type and Mechanism of Action, 2014

Figure 11: Ovarian Cancer Therapeutics, Global, Molecular Targets of the Developmental Pipeline, 2014

Figure 12: Ovarian Cancer Therapeutics, Global, Clinical Trial Duration (months), 2006–2014

Figure 13: Ovarian Cancer Therapeutics, Global, Clinical Trial Size (participants), 2006–2014

Figure 14: Ovarian Cancer Therapeutics, Global, Clinical Trial Failure Rate and Reasons for Failure (%), 2006–2014

Figure 15: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters – Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: All Patients

Figure 16: Ovarian Cancer Therapeutics, Safety Results for Key Parameters – Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: All Patients

Figure 17: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters – Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Sensitive

Figure 18: Ovarian Cancer Therapeutics, Safety Results for Key Parameters – Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Sensitive

Figure 19: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters – Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Resistant

Figure 20: Ovarian Cancer Therapeutics, Efficacy Results for Key Parameters – Pipeline (blue) and Marketed Products Comparison. Recurrent Disease: Platinum-Resistant

Figure 21: Ovarian Cancer Therapeutics, Global, Treatment Use Patterns and Market Size, 2013–2020

Figure 22: Ovarian Cancer Therapeutics, India, Treatment Use Patterns (‘000), 2013–2020

Figure 23: Ovarian Cancer Therapeutics, India, Annual Cost of Therapy ($), 2013–2020

Figure 24: Ovarian Cancer Therapeutics: India, Market Size ($m), 2013–2020

Figure 25: Ovarian Cancer Therapeutics, China, Treatment Use Patterns (‘000), 2013–2020

Figure 26: Ovarian Cancer Therapeutics, China, Annual Cost of Therapy ($), 2013–2020

Figure 27: Ovarian Cancer Therapeutics: China, Market Size ($m), 2013–2020

Figure 28: Ovarian Cancer Therapeutics, Japan, Treatment Use Patterns (‘000), 2013–2020

Figure 29: Ovarian Cancer Therapeutics, Japan, Annual Cost of Therapy ($), 2013–2020

Figure 30: Ovarian Cancer Therapeutics: Japan, Market Size ($m), 2013–2020

Figure 31: Ovarian Cancer Therapeutics, Australia, Treatment Use Patterns (‘000), 2013–2020

Figure 32: Ovarian Cancer Therapeutics, Australia, Annual Cost of Therapy ($), 2013–2020

Figure 33: Ovarian Cancer Therapeutics: Australia, Market Size ($m), 2013–2020

Figure 34: Ovarian Cancer Therapeutics, Global, Licensing Deals by Location, Year and Value, 2006–2014

Figure 35: Ovarian Cancer Therapeutics, Global, Licensing Deals by Phase, Molecule Type and Mechanism of Action, 2006–2014

Figure 36: Ovarian Cancer Therapeutics, Global, Co-development Deals by Location, Year and Value, 2006–2014

Figure 37: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *